Plus Therapeutics Q1 net loss $17.4M; cash jumps to $9.9M on $15M financing and grants

PLUS THERAPEUTICS, INC.

2025-Q1 EPS reported -$1.19 revenue$1,059,000

Cash balance $9.9M at Mar 31, 2025 vs $0.1M at Dec 31, 2024; raised $15M private placement and $2M grant advance.
Net loss $17.4M ($1.19/share) vs $3.3M ($0.75/share) in Q1 2024; operating loss $3.5M vs $3.3M.
Completed ReSPECT-LM Phase 1 dose trial; FDA Orphan Drug Designation for REYOBIQ for leptomeningeal metastases in lung cancer.
Published Phase 1 REYOBIQ data in Nature Communications: >100 Gy dose group median OS 17 months, double standard of care.
Added board member Kyle Guse; management hires: Dr. Rosol (CDO), Bradley (CNSide President), Stein (Medical Director).

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.